Literature DB >> 9177153

Fas-ligand: privilege and peril.

D R Green1, C F Ware.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9177153      PMCID： PMC33671          DOI： 10.1073/pnas.94.12.5986

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  37 in total

1.  Prevention of the induction of allospecific cytotoxic T lymphocyte and delayed-type hypersensitivity responses by ultraviolet irradiation of corneal allografts.

Authors:  J Y Niederkorn; D Callanan; J R Ross
Journal:  Transplantation       Date:  1990-08       Impact factor: 4.939

2.  Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

Authors:  J Allison; H M Georgiou; A Strasser; D L Vaux
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  Polymorphism of murine Fas ligand that affects the biological activity.

Authors:  N Kayagaki; N Yamaguchi; F Nagao; S Matsuo; H Maeda; K Okumura; H Yagita
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Human lung carcinomas express Fas ligand.

Authors:  G A Niehans; T Brunner; S P Frizelle; J C Liston; C T Salerno; D J Knapp; D R Green; R A Kratzke
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

5.  Fetal and postnatal testis shows immunoprivilege as donor tissue.

Authors:  M B Statter; R P Foglia; D E Parks; P K Donahoe
Journal:  J Urol       Date:  1988-01       Impact factor: 7.450

6.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

Authors:  S T Ju; D J Panka; H Cui; R Ettinger; M el-Khatib; D H Sherr; B Z Stanger; A Marshak-Rothstein
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

7.  Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis.

Authors:  C Giordano; G Stassi; R De Maria; M Todaro; P Richiusa; G Papoff; G Ruberti; M Bagnasco; R Testi; A Galluzzo
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

8.  A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse.

Authors:  A Matsuzawa; T Moriyama; T Kaneko; M Tanaka; M Kimura; H Ikeda; T Katagiri
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

9.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.

Authors:  S Yonehara; A Ishii; M Yonehara
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

10.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Authors:  J O'Connell; G C O'Sullivan; J K Collins; F Shanahan
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307
View more
  10 in total

Review 1.  Origin, regulation and physiological function of intestinal oeosinophils.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Best Pract Res Clin Gastroenterol       Date:  2008       Impact factor: 3.043

2.  Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression.

Authors:  H G Zhang; G Bilbao; T Zhou; J L Contreras; J Gómez-Navarro; M Feng; I Saito; J D Mountz; D T Curiel
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

3.  Proinflammatory consequences of transgenic fas ligand expression in the heart.

Authors:  D P Nelson; E Setser; D G Hall; S M Schwartz; T Hewitt; R Klevitsky; H Osinska; D Bellgrau; R C Duke; J Robbins
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

4.  Fas and Fas-ligand expression in human pancreatic cancer.

Authors:  M Kornmann; T Ishiwata; J Kleeff; H G Beger; M Korc
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

5.  Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies.

Authors:  K Tominaga; S Kuriyama; H Yoshiji; A Deguchi; Y Kita; F Funakoshi; T Masaki; K Kurokohchi; N Uchida; T Tsujimoto; H Fukui
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

6.  Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer.

Authors:  Motomu Shimizu; Takayuki Yoshimoto; Akio Matsuzawa; Yasutaka Takeda
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

7.  Adenoviral-mediated gene transfer in lymphocytes.

Authors:  R P Leon; T Hedlund; S J Meech; S Li; J Schaack; S P Hunger; R C Duke; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

8.  CD95 ligand (CD95L) in normal human lymphoid tissues: a subset of plasma cells are prominent producers of CD95L.

Authors:  J Sträter; S M Mariani; H Walczak; F G Rücker; F Leithäuser; P H Krammer; P Möller
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

Review 9.  CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target.

Authors:  Ayobami Matthew Olajuyin; Adefunke Kafayat Olajuyin; Ziqi Wang; Xingru Zhao; Xiaoju Zhang
Journal:  Cancer Cell Int       Date:  2019-09-26       Impact factor: 5.722

Review 10.  The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions.

Authors:  Xinyu Li; Qiang Meng; Lei Zhang
Journal:  J Immunol Res       Date:  2018-09-23       Impact factor: 4.818
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.